| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Annals of Surgical Oncology, Vol 4, Issue 1 46-56, Copyright © 1997 by Society of Surgical Oncology
ARTICLES |
P. M. Schneider, C. Fellbaum, U. Fink, E. Bollschweiler and H. W. Prauer
Department of Surgery, Technical University of Munich Medical Center, Germany.
BACKGROUND: The prognostic importance of various clinical variables (age, sex, association with myasthenia gravis), staging according to Masaoka, histologic type according to the Marino/Kirchner/Muller-Hermelink (MKM-H) classification, and residual tumor category (R category) was evaluated in a retrospective analysis. METHODS: Eighty-two patients with epithelial thymic tumors (ETTs) treated in the period 1969-1993 were evaluated, and archived specimens were histologically reclassified according to the classification of MKM-H. RESULTS: Age, sex, and association with myasthenia gravis were of no prognostic importance. The R category is of significant prognostic importance, with 5- and 10-year survival rates of 93.6% and 87.3%, respectively, for R0 resections compared with 0% at 5 years for R1 and R2 resections (p < 0.001). Staging (Masaoka) proved to be a prognostic factor (5-/10-year survival: stage I, 100%/90.9%; II, 95%/88.2%; III, 55.9%/46.6%; and IV, 10.8%/ 10.8%; p < 0.001). Histologic typing according to MKM-H is also of significant prognostic importance (5/10 year survival: thymomas: medullary, 100%/100%; mixed, 100%/100%, predominantly cortical, 68.6%/68.6%; cortical, 65.8%/65.8%; thymic carcinomas: well-differentiated type, 62.3%/44.5%; thymic carcinomas other than well-differentiated type, 33.6%/26.9%; p < 0.001). Multivariate analysis demonstrated that staging (p < 0.001), R category (p < 0.026), and MKM-H classification (p < 0.028) have an independent impact on survival. CONCLUSIONS: Staging (Masaoka), R category, and histologic classification (MKM-H) are important independent prognostic factors for patients with epithelial thymic tumors. Complete (R0) surgical resections should be the ultimate goal in the clinical management of patients with epithelial thymic tumors.
This article has been cited by other articles:
 |
|
 |
|
  A. A. Mangi, J. C. Wain, D. M. Donahue, H. C. Grillo, D. J. Mathisen, and C. D. Wright Adjuvant Radiation of Stage III Thymoma: Is It Necessary? Ann. Thorac. Surg., June 1, 2005; 79(6): 1834 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Venuta, E. A. Rendina, F. Longo, T. De Giacomo, M. Anile, E. Mercadante, L. Ventura, M. F. Osti, F. Francioni, and G. F. Coloni Long-term outcome after multimodality treatment for stage III thymic tumors Ann. Thorac. Surg., December 1, 2003; 76(6): 1866 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singhal, J. B. Shrager, D. I. Rosenthal, V. A. LiVolsi, and L. R. Kaiser Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation Ann. Thorac. Surg., November 1, 2003; 76(5): 1635 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Mangi, C. D. Wright, J. S. Allan, J. C. Wain, D. M. Donahue, H. C. Grillo, and D. J. Mathisen Adjuvant radiation therapy for stage II thymoma Ann. Thorac. Surg., October 1, 2002; 74(4): 1033 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Johnson, T. Y. Eng, G. Giaccone, and C. R. Thomas Jr. Thymoma: Update for the New Millenium Oncologist, June 1, 2001; 6(3): 239 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lardinois, R. Rechsteiner, R. H. Lang, M. Gugger, D. Betticher, C. von Briel, T. Krueger, and H.-B. Ris Prognostic relevance of Masaoka and Muller-Hermelink classification in patients with thymic tumors Ann. Thorac. Surg., May 1, 2000; 69(5): 1550 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Thomas, C. D. Wright, and P. J. Loehrer Thymoma: State of the Art J. Clin. Oncol., July 1, 1999; 17(7): 2280 - 2280. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
